Financial Report: Sanofi 3Q

Sanofi

3Q Revenues: €8.4 billion (-7%)

3Q Earnings: €1.8 billion (-19%)

YTD Revenues: €24.5 billion (-7%)

YTD Earnings: €4.9 billion (-26%)

Comments: Pharmaceutical sales were €6.7 million in the quarter, up 3%.Sales lost to generic competition on key legacy products in the U.S. and EU were €191 million. Diabetes sales were up 20% to €1.7 million with Lantus sales of €1.5 million (+21%). Vaccines sales were €1.3 billion (-7%) impacted by supply limitations of Pentaceland Adacel in the U.S. and the quarterly phasing of U.S. flu vaccines sales. Genzyme sales grew 21% to €529 million driven by the 11% growth of the rare disease franchise and the launch of Aubagio. Emerging Markets sales were €2.7 billion, up 3% and were impacted by lower growth in the Chinese pharmaceutical market and lower sales of Brazil generics. Consumer Healthcare grew 10% reflecting the launch of Rolaids in the U.S. and the improvement of the CHC business in China. Animal Health sales were €458 million, down 6% due to increased competition to Frontline.